Clinical Trials for Lung Cancer
957 lung cancer trials indexed, 466 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Lung Cancer
Lung cancer is a disease where abnormal cells grow uncontrollably in the lungs. These cells can form tumors that interfere with normal lung function. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), each with distinct biological features. Doctors diagnose lung cancer using imaging tests like X-rays and CT scans, followed by a biopsy to examine the tissue under a microscope. This process helps determine the cancer type and stage, which guides treatment decisions.
Common symptoms of lung cancer include a persistent cough, chest pain, shortness of breath, and coughing up blood. Fatigue and unexplained weight loss may also occur. Lung cancer most often affects people aged 65 or older, but it can occur at younger ages. The highest risk factor is smoking tobacco, which accounts for the majority of cases. Exposure to secondhand smoke, air pollution, radon gas, and certain workplace chemicals also increase risk. Genetics may play a role in some cases, especially among non-smokers.
Lung cancer is a major medical and social concern worldwide. It is the leading cause of cancer death, responsible for about 1.8 million deaths each year globally. In the United States, lung cancer accounts for nearly 25% of all cancer deaths. The economic burden is significant due to treatment costs and loss of productivity. Early detection is challenging because symptoms often appear late. This makes lung cancer one of the deadliest cancers and a priority for ongoing research and public health efforts.
The Lung Cancer Treatment Landscape
The first-line treatment for lung cancer depends on the type and stage of the disease. For early-stage NSCLC, surgery to remove the tumor is common, sometimes followed by chemotherapy or radiation to reduce recurrence risk. Advanced NSCLC often starts with systemic therapies such as chemotherapy, targeted therapy, or immunotherapy. Treatment is carefully sequenced based on tumor characteristics and patient health. For SCLC, chemotherapy combined with radiation is usually the initial approach because this cancer tends to spread quickly.
When first-line treatment stops working or the cancer returns, second- and third-line options come into play. These may include different chemotherapy drugs or newer targeted therapies that attack specific genetic mutations like EGFR or ALK. Immunotherapy drugs, such as checkpoint inhibitors, have become important for some patients. Established drugs in these classes include platinum-based chemotherapies and PD-1/PD-L1 inhibitors. The choice depends on prior treatments, cancer subtype, and biomarker testing results.
Despite advances, many patients still face challenges with current treatments. Some lung cancers develop resistance to drugs, making them less effective over time. Certain patient subgroups, including those with rare mutations, may have limited options. Side effects from chemotherapy and radiation can be severe, affecting quality of life. Research aims to close these gaps by finding new drugs with fewer side effects, overcoming resistance, and expanding targeted therapies to more patients.
Why Clinical Trials Matter for Lung Cancer
Clinical trials offer patients access to new treatments that are not yet widely available. They provide closer monitoring by healthcare teams and contribute to medical knowledge that can help future patients. Currently, there are 957 lung cancer clinical trials indexed on ClinicalTrials.gov, with 466 actively recruiting participants. These trials test a range of approaches, from new drugs to combinations of therapies, aiming to improve outcomes and reduce side effects.
Joining a clinical trial involves certain risks. New treatments may not work better than current options, and some trials include placebo groups. Participants often need to visit clinics more frequently for tests and monitoring. Side effects from experimental therapies can be unknown or more severe than standard treatments. It is important for patients to discuss these factors with their doctors and understand the trial’s purpose and procedures before enrolling.
The lung cancer clinical trial landscape includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative groups that collaborate to conduct research. ClinicalTrials.gov serves as a comprehensive registry where patients and caregivers can find information about ongoing trials. This registry helps connect people with studies that match their health status and treatment history, supporting informed decisions about participation.
What to Look for in a Lung Cancer Clinical Trial
Clinical trials for lung cancer are divided into phases 1 through 4. Phase 1 trials focus on testing a new treatment's safety and dosage in a small group of people. Phase 2 trials assess the treatment's effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to the current standard treatment in an even larger population. Phase 4 trials happen after a treatment is approved to monitor long-term effects. For lung cancer, most trials are in Phase 1 with 176 studies. Phase 2 follows with 146 trials. There are 86 trials where the phase is not available, and 84 trials are in Phase 3. This shows many studies are still early in testing new therapies.
When considering lung cancer clinical trials, certain inclusion criteria often apply. Age ranges can vary but usually include adults 18 years or older. Some trials focus on patients who have had specific prior treatments, such as chemotherapy or radiation. Biomarkers, which are biological signs found in blood or tumor tissue, may be required to match a treatment targeting those markers. Staging of lung cancer, which describes how advanced the disease is, is also important. Trials may only accept patients with early or late-stage lung cancer. The length of time someone has had the disease can affect eligibility, as some trials require recent diagnoses while others accept longer histories.
Exclusion criteria are just as important and help protect patient safety. Many trials exclude people with other serious health conditions, or comorbidities, that could interfere with treatment or increase risks. Drug interactions are a concern, so patients taking certain medications might not qualify. Safety thresholds such as minimum blood counts, liver and kidney function tests, and heart health are often required to ensure participants can handle the treatment. These rules help researchers collect clear data and keep participants safe during the study.
Practical considerations matter when deciding to join a lung cancer clinical trial. The length of the trial can range from a few months to several years, depending on the treatment and study goals. Visit schedules may be frequent, especially during early phases, requiring regular hospital or clinic trips. Travel distance can be a challenge if the trial site is far from home. Patients should ask the research team key questions: What are the possible side effects? How often will I need to visit the clinic? Will the trial cover travel and other costs? What happens if I decide to leave the trial early? Getting clear answers helps patients and caregivers make informed decisions about participation.
Primary Sources and Further Reading
Finding reliable information is important when learning about lung cancer clinical trials. The following sources offer trusted guidance on cancer treatments, clinical trial processes, and patient support. These websites are maintained by government health agencies and research institutions. They provide up-to-date facts, detailed explanations, and resources for patients and caregivers.
- National Cancer Institute: Lung Cancer
- ClinicalTrials.gov: Lung Cancer Trials
- MedlinePlus: Lung Cancer
- Centers for Disease Control and Prevention: Lung Cancer
Latest Research and Emerging Treatments for Lung Cancer (2026)
New lung cancer treatments are being studied to improve outcomes for patients with different types of this disease. One promising approach combines durvalumab and domvanalimab, two immunotherapy drugs, after chemoradiation in patients with stage III unresectable non-small cell lung cancer (NSCLC). Durvalumab helps the immune system recognize and attack cancer cells by blocking a protein called PD-L1. Domvanalimab targets a different immune checkpoint, TIGIT, which may boost the immune response further. This combination is being tested to see if it can better control the disease and extend survival compared to current treatments (NCT05211895).
For patients with limited-stage small cell lung cancer (LS-SCLC), a new drug called tarlatamab is under study following chemoradiotherapy. Tarlatamab is a type of therapy designed to engage the immune system by binding to specific proteins on cancer cells and immune cells, encouraging the body to attack the tumor. This Phase 3 trial is exploring whether tarlatamab can improve survival for this aggressive lung cancer type (NCT06117774). If successful, it could offer a new option beyond traditional chemotherapy and radiation.
Another area of lung cancer research focuses on targeted treatments for specific genetic mutations. Zipalertinib is being tested in patients with early-stage NSCLC who have uncommon mutations in the EGFR gene. This drug works by blocking signals that help cancer cells grow and divide. It is combined with chemotherapy to see if it can reduce the chance of cancer returning after surgery (NCT07128199). These new drugs for lung cancer may provide more personalized treatment options and improve disease-free survival for patients. Overall, lung cancer research in 2026 is exploring immunotherapy combinations and targeted therapies to offer better lung cancer treatment choices for patients.
Frequently asked questions about Lung Cancer trials
How do I find Lung Cancer clinical trials?
The authoritative source for Lung Cancer clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 957 lung cancer studies are currently indexed. You can search by entering "lung cancer" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new lung cancer trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Lung Cancer trials in?
Across the 957 lung cancer trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Lung Cancer clinical trials are currently recruiting?
As of the latest scan, 466 lung cancer trials have a "Recruiting" status on ClinicalTrials.gov, out of 957 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting lung cancer trial matches their tracked condition.
Stay informed about lung cancer research
Get a weekly briefing with the trials that matter most.